Tumor-Targeted and Clearable Human Protein-Based MRI Nanoprobes

被引:66
作者
Zhao, Yang [1 ,2 ,3 ]
Peng, Jing [1 ]
Li, Jingjin [1 ]
Huang, Ling [3 ]
Yang, Jinyi [3 ]
Huang, Kai [3 ]
Li, Hewen [1 ]
Jiang, Ning [3 ]
Zheng, Shaokuan [3 ]
Zhang, Xuening [1 ]
Niu, Yuanjie [2 ]
Han, Gang [3 ]
机构
[1] Tianjin Med Univ, Dept Radiol, Hosp 2, Tianjin 300211, Peoples R China
[2] Tianjin Inst Urol, Sex Hormone Res Ctr, Tianjin 300211, Peoples R China
[3] Univ Massachusetts, Sch Med, Biochem & Mol Pharmacol, 364 Plantat St,LRB 806, Worcester, MA 01605 USA
基金
中国国家自然科学基金; 美国国家卫生研究院;
关键词
Magnetic resonance imaging; magnetic nanoparticles; protein; tumor targeting; clearance; NEAR-INFRARED FLUORESCENCE; IMAGING IN-VIVO; CONTRAST AGENTS; DRUG-DELIVERY; TRANSFERRIN RECEPTORS; DIRECTED SYNTHESIS; NANOPARTICLES; CANCER; ALBUMIN; FABRICATION;
D O I
10.1021/acs.nanolett.7b00828
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Biocompatibility, targeting, and clearance are key challenges in the design of new MRI contrast agents. Herein, we report on a tumor-targeting, gadolinium biomineralized human transferrin (Tf) protein-based nanoparticle (Gd@Tf NP) for MRI use. As compared to the conventionally used gadolinium chelates, the resultant Gd@Tf NPs possess outstanding chemical stability and exhibited superior longitudinal relaxation. More importantly, our MR images show that Gd@Tf indeed retained the natural tumor targeting ability and the subsequent tumor retrieval biofunctions of Tf. Thus, such Tf protein-based MR NPs integrate T1 signal amplification, precise tumor targeting, and systematic clearance capabilities. They offer a new approach to design biocompatible multifunctional MRI contrast agents for a wide range of clinical imaging and treatment applications.
引用
收藏
页码:4096 / 4100
页数:5
相关论文
共 31 条
[1]   Gadolinium(III) chelates as MRI contrast agents: Structure, dynamics, and applications [J].
Caravan, P ;
Ellison, JJ ;
McMurry, TJ ;
Lauffer, RB .
CHEMICAL REVIEWS, 1999, 99 (09) :2293-2352
[2]   Long-Term Effects of Nanoparticles on Nutrition and Metabolism [J].
Chen, Nan ;
Wang, Hui ;
Huang, Qing ;
Li, Jiang ;
Yan, Juan ;
He, Dannong ;
Fan, Chunhai ;
Song, Haiyun .
SMALL, 2014, 10 (18) :3603-3611
[3]   Transferrin gated mesoporous silica nanoparticles for redox-responsive and targeted drug delivery [J].
Chen, Xiaolu ;
Sun, Hui ;
Hu, Jun ;
Han, Xia ;
Liu, Honglai ;
Hu, Ying .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2017, 152 :77-84
[4]  
FAULK WP, 1980, LANCET, V2, P390
[5]   Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer [J].
Gradishar, WJ ;
Tjulandin, S ;
Davidson, N ;
Shaw, H ;
Desai, N ;
Bhar, P ;
Hawkins, M ;
O'Shaughnessy, J .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :7794-7803
[6]   Measurement of glomerular filtration rate with magnetic resonance imaging: Principles, limitations, and expectations [J].
Grenier, Nicolas ;
Mendichovszky, Iosif ;
De Senneville, Baudouin Denis ;
Rouiol, Sbastien ;
Desbarats, Pascal ;
Pedersen, Michael ;
Wells, Kevin ;
Frokiaer, Jorgen ;
Gordon, Isky .
SEMINARS IN NUCLEAR MEDICINE, 2008, 38 (01) :47-55
[7]   IDENTIFICATION OF TRANSFERRIN RECEPTORS ON THE SURFACE OF HUMAN CULTURED-CELLS [J].
HAMILTON, TA ;
WADA, HG ;
SUSSMAN, HH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (12) :6406-6410
[8]   Enhancing Glioblastoma-Specific Penetration by Functionalization of Nanoparticles with an Iron-Mimic Peptide Targeting Transferrin/Transferrin Receptor Complex [J].
Kang, Ting ;
Jiang, Mengyin ;
Jiang, Di ;
Feng, Xingye ;
Yao, Jianhui ;
Song, Qingxiang ;
Chen, Hongzhuan ;
Gao, Xiaoling ;
Chen, Jun .
MOLECULAR PHARMACEUTICS, 2015, 12 (08) :2947-2961
[9]   Determination of Proton Relaxivities of Mn(II), Cu(II) and Cr(III) added to Solutions of Serum Proteins [J].
Koylu, Mehmet Zafer ;
Asubay, Sezai ;
Yilmaz, Ali .
MOLECULES, 2009, 14 (04) :1537-1545
[10]   Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles [J].
Kratz, Felix .
JOURNAL OF CONTROLLED RELEASE, 2008, 132 (03) :171-183